Waldron Private Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

Waldron Private Wealth’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$244K	Buy	+780	New	+$231K	0.01%	313

Other funds holding LGND

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Waldron Private Wealth's LGND Position: Q3 2026 in Review

Waldron Private Wealth opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2026: 780 shares worth $244K. The stake represents 0.01% of the portfolio and ranks #313 among its holdings.

246 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

Waldron Private Wealth held 780 shares of Ligand Pharmaceuticals worth $244K as of Q3 2026.
Ligand Pharmaceuticals was a new Waldron Private Wealth position in Q3 2026.
Ligand Pharmaceuticals made up 0.01% of Waldron Private Wealth's portfolio in Q3 2026, its #313 holding.
246 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Waldron Private Wealth's 13F filing for Q3 2026, filed 2 Nov 2026.